Trial Profile

A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evofosfamide (Primary) ; Ipilimumab (Primary)
Indications Head and neck cancer; Malignant melanoma; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Threshold Pharmaceuticals

16 Jun 2021 Results published in the ImmunoGenesis Media Release
26 Mar 2021 Results assessing (n=21; Median age= 67 years) safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of combining evofosfamide and ipilimumab in patients with advanced solid tumors, published in the Clinical Cancer Research.
13 Jun 2017 According to a Threshold Pharmaceuticals media release, first patient has been dosed in the trial at the University of Texas MD Anderson Cancer Center.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com